Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxapram versus placebo in preterm newborns
2019-003666-41Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in apnea of prematurity (AOP) and respiratory failure of prematurity (RFP) comparing Doxapram with Placebo (2 arms). Primary endpoint: Death or severe disability at 2 years corrected age. Started Feb 2020; status: active.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)respiratory failure of prematurity (RFP)
Beyond the preview
Go deeper on 2019-003666-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003666-41.